Download Image
    
Share
  
Post
Ibuzatrelvir for COVID-19
1 study with 126 patients
Significantly lower risk for viral clearance.
COVID-19 Ibuzatrelvir studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 27% Viral clearance 27% RCTs 27% Early 27% Favorsibuzatrelvir Favorscontrol
Nov 21
 Covid Analysis Ibuzatrelvir for COVID-19: real-time meta analysis of 1 study
Significantly lower risk is seen for viral clearance. Meta analysis using the most serious outcome reported shows 27% [15‑38%] lower risk. Currently there is very limited data, with only one study to date. No treatment is 100% ..
Nov 2
2024
 Mortezavi et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae529 Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
27% improved viral clearance (p=0.0001). RCT 240 outpatients showing significant viral load reduction with ibuzatrelvir (an oral SARS-CoV-2 Mpro inhibitor) compared to placebo. The study enrolled non-hospitalized adults aged 18-65 with symptomatic COVID-19 (≤5 days) and positive..
Jul 5
2024
 Brewitz et al., Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.4c01342 Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment
Perspective article discussing the development of ibuzatrelvir (PF-07817883) as a SARS-CoV-2 main protease (Mpro) inhibitor which addresses the metabolic instability of nirmatrelvir and does not require co-administration with ritonavir, t..